Journal
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Volume 12, Issue 5, Pages 126-129Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/0973-1482.191638
Keywords
Intrathecal therapy; leptomeningeal metastasis; nimotuzumab; nonsmall cell lung cancer
Categories
Ask authors/readers for more resources
Leptomeningeal metastasis (LM) carries a devastating prognosis. Treatment selection is limited for patients with LM. We introduced to use nimotuzumab (also known as h-R3) for treating LM of nonsmall cell lung cancer. Here, we report two patients in our treatment who had prolonged overall survival over 1 year each. The pressure of cerebrospinal fluid of the patients decreased remarkably after intrathecal therapy. Symptoms of the patients had been improved quickly after one or two times of intrathecal therapy. Nimotuzumab was well tolerated used in intrathecal therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available